Dementia incidence varied by anticancer drugs and molecular targeted therapy in a population-based cohort study.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

Antineoplastic Agents*/therapeutic use ; Molecular Targeted Therapy* ; Dementia*/epidemiology ; Dementia*/drug therapy ; Neoplasms*/epidemiology ; Neoplasms*/drug therapy; Humans ; Male ; Aged ; Female ; Incidence ; Retrospective Studies ; Republic of Korea/epidemiology ; Aged, 80 and over ; Proportional Hazards Models ; Alzheimer Disease/epidemiology ; Alzheimer Disease/drug therapy ; Cohort Studies

Anticancer drugs may affect the incidence of dementia by modulating the common pathophysiology between cancer and dementia. However, there is a paucity of research that focused on anticancer drugs with different mechanisms of action and their associations with subtypes of dementia. Therefore, we aimed to investigate the incidence of dementia according to various groups of anticancer drugs. From the Korea National Health Insurance Service database, our retrospective population-based cohort study enrolled 116,506 cancer patients aged 65 years and older who received anticancer drugs between January 1, 2008 and December 31, 2018. The hazard ratio was determined using Cox proportional hazards regression models, comparing each group of anticancer drugs to all other anticancer drugs, after adjusting for covariates. Antimetabolites (HR = 0.91; 95% CI 0.84-0.97) and molecular targeted therapies (HR = 0.60; 95% CI 0.49-0.74) were associated with a decreased incidence of dementia of the Alzheimer type (DAT), but not with vascular dementia. Among molecular targeted therapies, epidermal growth factor receptor inhibitors (HR = 0.60; 95% CI 0.46-0.79) and multikinase inhibitors (HR = 0.49; 95% CI 0.27-0.89) were associated with a low incidence of DAT only. Our findings highlight the potential for targeted repurposing of anticancer drugs to prevent dementia.
(© 2024. The Author(s).)

Sci Rep. 2019 Feb 21;9(1):2516. (PMID: 30792526)
Neuroscience. 2009 Sep 15;162(4):1220-31. (PMID: 19447162)
Front Pharmacol. 2023 Aug 02;14:1238639. (PMID: 37601068)
Front Oncol. 2020 Feb 04;10:73. (PMID: 32117730)
Curr Probl Cancer. 2020 Dec;44(6):100578. (PMID: 32360240)
Proc Natl Acad Sci U S A. 2012 Oct 9;109(41):16743-8. (PMID: 23019586)
Andrology. 2016 May;4(3):481-5. (PMID: 27062333)
BMJ. 2012 Mar 12;344:e1442. (PMID: 22411920)
PLoS One. 2020 Dec 30;15(12):e0244660. (PMID: 33378392)
Cell Death Dis. 2011 Jun 02;2:e167. (PMID: 21633390)
Alzheimers Res Ther. 2023 Feb 28;15(1):39. (PMID: 36849969)
Int J Mol Sci. 2020 May 14;21(10):. (PMID: 32423175)
Int J Epidemiol. 2017 Apr 1;46(2):e15. (PMID: 26822938)
Lancet. 2015 Oct 24;386(10004):1698-706. (PMID: 26595643)
J Alzheimers Dis. 2017;60(2):461-481. (PMID: 28869476)
Neural Regen Res. 2022 Sep;17(9):1913-1918. (PMID: 35142667)
Neurology. 2013 Jul 23;81(4):322-8. (PMID: 23843468)
Am J Clin Oncol. 2010 Dec;33(6):533-43. (PMID: 20023570)
Alzheimers Res Ther. 2021 May 5;13(1):96. (PMID: 33952306)
Neurology. 2010 Jan 12;74(2):106-12. (PMID: 20032288)
Alzheimers Dement. 2020 Jul;16(7):953-964. (PMID: 32432415)
Alzheimers Dement. 2017 Dec;13(12):1364-1370. (PMID: 28711346)
Front Genet. 2024 Jan 05;14:1180905. (PMID: 38250575)
Sci Rep. 2019 Sep 19;9(1):13548. (PMID: 31537833)
Mol Neurobiol. 2019 Oct;56(10):7173-7187. (PMID: 30993533)
Eur Heart J. 2020 Oct 1;41(37):3521-3529. (PMID: 32542362)
ACS Chem Neurosci. 2016 Aug 17;7(8):1047-56. (PMID: 27046396)
Cell Mol Life Sci. 2020 Jul;77(14):2659-2680. (PMID: 31884567)
J Alzheimers Dis. 2014;42(2):565-73. (PMID: 24906231)
Pharmacol Ther. 2022 Sep;237:108171. (PMID: 35304223)
Proc Natl Acad Sci U S A. 2017 Apr 11;114(15):E3129-E3138. (PMID: 28351972)
Alzheimers Res Ther. 2020 Apr 6;12(1):38. (PMID: 32252806)
Alzheimers Dement. 2021 Sep;17(9):1415-1421. (PMID: 33656287)
Alzheimers Dement (N Y). 2017 Nov 09;3(4):612-621. (PMID: 29201995)
J Alzheimers Dis. 2022;89(1):367-380. (PMID: 35871349)
ACS Omega. 2021 May 19;6(21):13870-13887. (PMID: 34095679)
Int J Oncol. 2013 Jun;42(6):2123-33. (PMID: 23563930)

Keywords: Alzheimer’s disease; Anticancer drug; Cancer; Dementia; Incidence; Vascular dementia

0 (Antineoplastic Agents)

Date Created: 20240730 Date Completed: 20240730 Latest Revision: 20240807

20240807

PMC11289456

10.1038/s41598-024-68199-9

39080315